Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan

J Formos Med Assoc. 2018 May;117(5):381-403. doi: 10.1016/j.jfma.2017.09.007. Epub 2017 Oct 24.

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality in Taiwan. To help clinical physicians to manage patients with HCC, the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan produced the management consensus guideline for HCC.

Methods: The recommendations focus on nine important issues on management of HCC, including surveillance, diagnosis, staging, surgery, local ablation, transarterial chemoembolization/transarterial radioembolization/hepatic arterial infusion chemotherapy, systemic therapy, radiotherapy, and prevention.

Results: The consensus statements were discussed, debated and got consensus in each expert team. And then the statements were sent to all of the experts for further discussion and refinement. Finally, all of the experts were invited to vote for the statements, including the level of evidence and recommendation.

Conclusion: With the development of the management consensus guideline, HCC patients could benefit from the optimal therapeutic modality.

Keywords: Diagnosis; Hepatocellular carcinoma; Staging; Surveillance; Treatment.

MeSH terms

  • Carcinoma, Hepatocellular / prevention & control
  • Carcinoma, Hepatocellular / therapy*
  • Consensus*
  • Gastroenterology
  • Hepatitis B / complications
  • Hepatitis C / complications
  • Humans
  • Liver Neoplasms / prevention & control
  • Liver Neoplasms / therapy*
  • Practice Guidelines as Topic*
  • Societies, Medical
  • Taiwan